AU2014240404B2 - Manufacture of peanut formulations for oral desensitization - Google Patents

Manufacture of peanut formulations for oral desensitization

Info

Publication number
AU2014240404B2
AU2014240404B2 AU2014240404A AU2014240404A AU2014240404B2 AU 2014240404 B2 AU2014240404 B2 AU 2014240404B2 AU 2014240404 A AU2014240404 A AU 2014240404A AU 2014240404 A AU2014240404 A AU 2014240404A AU 2014240404 B2 AU2014240404 B2 AU 2014240404B2
Authority
AU
Australia
Prior art keywords
peanut
ara
glidant
lubricant
diluent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2014240404A
Other languages
English (en)
Other versions
AU2014240404A1 (en
Inventor
Howard V. Raff
Bryan Walser
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Societe des Produits Nestle SA
Original Assignee
Societe des Produits Nestle SA
Nestle SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51528061&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2014240404(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Societe des Produits Nestle SA, Nestle SA filed Critical Societe des Produits Nestle SA
Publication of AU2014240404A1 publication Critical patent/AU2014240404A1/en
Application granted granted Critical
Publication of AU2014240404B2 publication Critical patent/AU2014240404B2/en
Priority to AU2016231523A priority Critical patent/AU2016231523B2/en
Priority to AU2018222980A priority patent/AU2018222980A1/en
Priority to AU2020202685A priority patent/AU2020202685B2/en
Assigned to SOCIETE DES PRODUITS NESTLE S.A. reassignment SOCIETE DES PRODUITS NESTLE S.A. Request for Assignment Assignors: AIMMUNE THERAPEUTICS, INC.
Priority to AU2022201858A priority patent/AU2022201858B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/07—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of capsules or similar small containers for oral use
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Transplantation (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
AU2014240404A 2013-03-14 2014-03-12 Manufacture of peanut formulations for oral desensitization Active AU2014240404B2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2016231523A AU2016231523B2 (en) 2013-03-14 2016-09-21 Manufacture of peanut formulations for oral desensitization
AU2018222980A AU2018222980A1 (en) 2013-03-14 2018-08-30 Manufacture of peanut formulations for oral desensitization
AU2020202685A AU2020202685B2 (en) 2013-03-14 2020-04-22 Manufacture of peanut formulations for oral desensitization
AU2022201858A AU2022201858B2 (en) 2013-03-14 2022-03-17 Manufacture of peanut formulations for oral desensitization

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361784964P 2013-03-14 2013-03-14
US61/784,964 2013-03-14
PCT/US2014/024401 WO2014159607A1 (en) 2013-03-14 2014-03-12 Manufacture of peanut formulations for oral desensitization

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2016231523A Division AU2016231523B2 (en) 2013-03-14 2016-09-21 Manufacture of peanut formulations for oral desensitization

Publications (2)

Publication Number Publication Date
AU2014240404A1 AU2014240404A1 (en) 2015-09-17
AU2014240404B2 true AU2014240404B2 (en) 2016-07-21

Family

ID=51528061

Family Applications (5)

Application Number Title Priority Date Filing Date
AU2014240404A Active AU2014240404B2 (en) 2013-03-14 2014-03-12 Manufacture of peanut formulations for oral desensitization
AU2016231523A Active AU2016231523B2 (en) 2013-03-14 2016-09-21 Manufacture of peanut formulations for oral desensitization
AU2018222980A Abandoned AU2018222980A1 (en) 2013-03-14 2018-08-30 Manufacture of peanut formulations for oral desensitization
AU2020202685A Active AU2020202685B2 (en) 2013-03-14 2020-04-22 Manufacture of peanut formulations for oral desensitization
AU2022201858A Active AU2022201858B2 (en) 2013-03-14 2022-03-17 Manufacture of peanut formulations for oral desensitization

Family Applications After (4)

Application Number Title Priority Date Filing Date
AU2016231523A Active AU2016231523B2 (en) 2013-03-14 2016-09-21 Manufacture of peanut formulations for oral desensitization
AU2018222980A Abandoned AU2018222980A1 (en) 2013-03-14 2018-08-30 Manufacture of peanut formulations for oral desensitization
AU2020202685A Active AU2020202685B2 (en) 2013-03-14 2020-04-22 Manufacture of peanut formulations for oral desensitization
AU2022201858A Active AU2022201858B2 (en) 2013-03-14 2022-03-17 Manufacture of peanut formulations for oral desensitization

Country Status (19)

Country Link
US (5) US9198869B2 (enExample)
EP (3) EP3998080A1 (enExample)
JP (3) JP6752140B2 (enExample)
CN (2) CN105101994B (enExample)
AU (5) AU2014240404B2 (enExample)
BR (1) BR112015021756B1 (enExample)
CA (1) CA2903229A1 (enExample)
DK (2) DK3482771T3 (enExample)
ES (2) ES2826224T3 (enExample)
FI (2) FI3482771T3 (enExample)
FR (1) FR23C1026I2 (enExample)
HU (1) HUE051831T2 (enExample)
MX (1) MX2015010315A (enExample)
NL (1) NL301236I2 (enExample)
NO (1) NO2023027I1 (enExample)
PL (1) PL2968529T3 (enExample)
PT (1) PT2968529T (enExample)
SI (1) SI2968529T1 (enExample)
WO (1) WO2014159607A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2924349B1 (fr) 2007-12-03 2010-01-01 Dbv Tech Methode de desensibilitation aux allergenes
US9492535B2 (en) 2013-03-14 2016-11-15 Aimmune Therapeutics, Inc. Peanut formulations and uses thereof
SI2968529T1 (sl) 2013-03-14 2021-03-31 Aimmune Therapeutics, Inc. Izdelava arašidovih formulacij arašida za ustno desenzibilizacijo
KR102541110B1 (ko) 2014-08-25 2023-06-08 에이뮨 테라퓨틱스, 인코퍼레이티드 난 단백질 제형 및 이의 제조 방법
MA41020A (fr) 2014-11-25 2017-10-03 Evelo Biosciences Inc Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome
FI3258962T3 (fi) 2015-02-20 2023-04-12 Sekoitetut allergeenikoostumukset ja menetelmät niiden käyttämiseksi
US10149904B2 (en) 2015-02-20 2018-12-11 The Board Of Trusteees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
US10166286B2 (en) 2015-02-20 2019-01-01 The Board Of Trustees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
US11452774B2 (en) 2015-02-20 2022-09-27 The Board Of Trustees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
US10143742B2 (en) 2015-02-20 2018-12-04 The Board Of Trustees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
TW201709926A (zh) * 2015-04-23 2017-03-16 賽諾菲公司 用於舌下投藥之吡喃葡萄糖基脂ａ及過敏原調配物
US10856567B2 (en) 2016-07-22 2020-12-08 Kari Brown Baby food products containing allergenic proteins and methods of delivering same
PT3548079T (pt) * 2016-12-05 2023-07-27 Reacta Biotech Ltd Formulações de refeições para provocação oral
MX2019008419A (es) * 2017-01-13 2019-12-02 Aimmune Therapeutics Inc Métodos de fabricación de harinas de nueces y formulaciones para inmunoterapia oral.
BR102017026619A2 (pt) 2017-02-15 2018-10-30 Euroimmun Medizinische Labordiagnostika Ag ensaio melhorado para a diagnose de alergia a amendoim
US11382934B2 (en) 2017-07-18 2022-07-12 Before Brands, Inc. Methods for making mixed allergen compositions
CA3080601A1 (en) 2017-11-02 2019-05-09 Aimmune Therapeutics, Inc. Methods of oral immunotherapy
GB201718342D0 (en) * 2017-11-06 2017-12-20 Cambridge Allergy Ltd Allergenic protein formulations for immunotherapy
SG11202006732WA (en) 2018-01-16 2020-08-28 Tel Hashomer Medical Res Infrastructure & Services Ltd Treatment and prevention of seed allergies
CN112638413A (zh) 2018-07-27 2021-04-09 艾慕恩治疗公司 口服免疫治疗单位剂量分配系统和方法
EP3836801A4 (en) 2018-08-16 2022-05-18 Société des Produits Nestlé S.A. Peanut oral immunotherapy with maintenance dose
AU2019401576A1 (en) * 2018-12-17 2021-06-24 Société des Produits Nestlé S.A. Formulations for egg oral immunotherapy, methods of manufacture, and treatments for egg allergy
CN113891722A (zh) * 2018-12-20 2022-01-04 爱沐疗法公司 用于漏服剂量的花生口服免疫疗法给药计划表
CA3127337A1 (en) 2019-01-23 2020-07-30 Before Brands, Inc. Methods for making mixed allergen compositions
EP3965815A4 (en) 2019-05-10 2023-05-31 Société des Produits Nestlé S.A. METHOD OF IMPROVING THE QUALITY OF LIFE IN A PEANUT ALLERGY PATIENT
MX2022001568A (es) * 2019-08-08 2022-03-02 Evonik Operations Gmbh Procedimiento de preparacion de una forma de dosificacion solida y un lubricante.
WO2021102186A1 (en) * 2019-11-20 2021-05-27 Aimmune Therapeutics, Inc. Methods and systems for managing distribution and treatment of a food allergy oral immunotherapy drug
EP4081251A4 (en) * 2019-12-23 2024-03-20 Prota Therapeutics Pty Ltd PHARMACEUTICAL COMPOSITIONS
US12357226B2 (en) 2020-07-01 2025-07-15 Société des Produits Nestlé S.A. Determining medical staffing for oral immunotherapy
AU2022206434A1 (en) 2021-01-08 2023-08-24 Regeneron Pharmaceuticals, Inc. Methods for treating peanut allergy and enhancing peanut allergen-specific immunotherapy by administering an il-4r antagonist
CA3255134A1 (en) 2022-04-11 2023-10-19 Alk Abello As PEANUT ALLERGEN COMPOSITION

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012123759A1 (en) * 2011-03-17 2012-09-20 Cambridge Enterprise Limited Treatment for peanut allergy

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3809767A (en) * 1969-05-12 1974-05-07 Griffith Laboratories Methods of making vegetable protein concentrates
WO1992015285A1 (en) 1991-03-01 1992-09-17 Warner-Lambert Company Starch-based controlled release compositions
US20120164306A1 (en) * 1993-08-03 2012-06-28 Girsh Leonard S Process for preparing hypoallergenic and reduced fat foods
JP3445593B2 (ja) * 1994-09-10 2003-09-08 株式会社林原生物化学研究所 ペプチドとその用途
WO2001040264A2 (en) 1999-12-06 2001-06-07 Panacea Pharmaceuticals, Llc. Peptide antigens
ES2260078T3 (es) 2000-04-06 2006-11-01 Seer Pharmaceuticals, Llc. Sistema de administracion microbiana.
WO2004075875A1 (en) 2003-02-28 2004-09-10 Alk-Abello A/S Dosage form having a saccharide matrix
EP2545931A1 (en) 2004-03-19 2013-01-16 Herbs Spring, LLC Herbal therapy for the treatment of food allergy
JP2009522258A (ja) * 2005-12-28 2009-06-11 テバ ファーマシューティカル インダストリーズ リミティド 増大したバイオアベイラビリティを有するフェノフィブラートの医薬製剤
FR2924349B1 (fr) * 2007-12-03 2010-01-01 Dbv Tech Methode de desensibilitation aux allergenes
WO2010059534A2 (en) 2008-11-19 2010-05-27 Mallinckrodt Baker, Inc. Directly compressible granular microcrystalline cellulose based excipient, manufacturing process and use thereof
CA2737335C (en) 2008-12-19 2013-10-01 Merz Pharma Gmbh & Co. Kgaa 1-amino-alkylcyclohexane derivatives for the treatment of mast cell mediated diseases
US8329208B2 (en) 2009-07-28 2012-12-11 Methylation Sciences International Srl Pharmacokinetics of S-adenosylmethionine formulations
EP2364690A1 (en) 2010-02-12 2011-09-14 Centro De Ingenieria Genetica Y Biotecnologia Orally administrable pharmaceutical pellet of epidermal growth factor
JP5800527B2 (ja) * 2010-03-30 2015-10-28 日東電工株式会社 安定化医薬組成物、安定化医薬組成物溶液製剤、フィルム状製剤及びフィルム状製剤の製造方法
AR081776A1 (es) * 2010-06-30 2012-10-17 Novartis Ag Composiciones farmaceuticas que comprenden monohidrato de lactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1h-bencimidazol-2-il]-1h-quinolin-2-ona, proceso para la produccion de la composicion
CN101912364B (zh) * 2010-08-09 2015-07-15 刘会梅 银杏内酯b脂质体组合药物
JP2014525458A (ja) * 2011-08-31 2014-09-29 ペロスフィア インコーポレイテッド アレルギー患者を有効かつ迅速に脱感作するための方法
WO2013087119A1 (en) * 2011-12-16 2013-06-20 Hal Allergy Holding B.V. Pharmaceutical formulations and the use thereof for the treatment of peanut allergy
US9492535B2 (en) * 2013-03-14 2016-11-15 Aimmune Therapeutics, Inc. Peanut formulations and uses thereof
SI2968529T1 (sl) 2013-03-14 2021-03-31 Aimmune Therapeutics, Inc. Izdelava arašidovih formulacij arašida za ustno desenzibilizacijo
KR102541110B1 (ko) 2014-08-25 2023-06-08 에이뮨 테라퓨틱스, 인코퍼레이티드 난 단백질 제형 및 이의 제조 방법
MX2019008419A (es) 2017-01-13 2019-12-02 Aimmune Therapeutics Inc Métodos de fabricación de harinas de nueces y formulaciones para inmunoterapia oral.
CA3080601A1 (en) 2017-11-02 2019-05-09 Aimmune Therapeutics, Inc. Methods of oral immunotherapy

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012123759A1 (en) * 2011-03-17 2012-09-20 Cambridge Enterprise Limited Treatment for peanut allergy

Also Published As

Publication number Publication date
CN105101994A (zh) 2015-11-25
ES2826224T3 (es) 2021-05-17
FR23C1026I1 (fr) 2023-10-06
FI3482771T3 (fi) 2023-04-03
JP2019108357A (ja) 2019-07-04
ES2940686T3 (es) 2023-05-10
BR112015021756B1 (pt) 2023-01-10
US20140271836A1 (en) 2014-09-18
FIC20230022I1 (fi) 2023-07-04
FR23C1026I2 (fr) 2024-07-26
AU2020202685B2 (en) 2022-01-20
AU2016231523A1 (en) 2016-10-06
CA2903229A1 (en) 2014-10-02
US20230120350A1 (en) 2023-04-20
BR112015021756A2 (pt) 2017-07-18
DK2968529T3 (da) 2020-10-12
US20160030289A1 (en) 2016-02-04
AU2022201858B2 (en) 2024-04-04
EP3482771A1 (en) 2019-05-15
EP3998080A1 (en) 2022-05-18
US20200129378A1 (en) 2020-04-30
DK3482771T3 (da) 2023-03-20
JP6752140B2 (ja) 2020-09-09
AU2018222980A1 (en) 2018-09-20
EP3482771B1 (en) 2023-01-18
US9198869B2 (en) 2015-12-01
PL2968529T3 (pl) 2021-04-19
WO2014159607A1 (en) 2014-10-02
US10449118B2 (en) 2019-10-22
AU2020202685A1 (en) 2020-05-14
CN105101994B (zh) 2018-10-12
NL301236I2 (nl) 2025-07-31
AU2022201858A1 (en) 2022-04-07
HUE051831T2 (hu) 2021-03-29
EP2968529B1 (en) 2020-08-05
NO2023027I1 (no) 2023-07-06
BR112015021756A8 (pt) 2019-11-19
JP2021073321A (ja) 2021-05-13
HK1217660A1 (zh) 2017-01-20
MX2015010315A (es) 2016-04-13
CN109125283A (zh) 2019-01-04
PT2968529T (pt) 2020-11-10
US20180042816A1 (en) 2018-02-15
JP7454519B2 (ja) 2024-03-22
SI2968529T1 (sl) 2021-03-31
EP2968529A1 (en) 2016-01-20
EP2968529A4 (en) 2016-10-05
US11141352B2 (en) 2021-10-12
AU2014240404A1 (en) 2015-09-17
AU2016231523B2 (en) 2018-05-31
JP2016512537A (ja) 2016-04-28
JP6891205B2 (ja) 2021-06-18

Similar Documents

Publication Publication Date Title
AU2022201858B2 (en) Manufacture of peanut formulations for oral desensitization
KR102541110B1 (ko) 난 단백질 제형 및 이의 제조 방법
WO2018132733A1 (en) Methods of manufacture of nut flours and formulations for oral immunotherapy
WO2014159609A1 (en) Peanut formulations and uses thereof
HK40008413A (en) Manufacture of peanut formulations for oral desensitization
HK40008413B (en) Manufacture of peanut formulations for oral desensitization
HK40003142A (en) Manufacture of peanut formulations for oral desensitization
HK1217660B (zh) 用於口服脱敏的花生制剂的制备

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: SOCIETE DES PRODUITS NESTLE S.A.

Free format text: FORMER OWNER(S): AIMMUNE THERAPEUTICS, INC.

GD Licence registered

Name of requester: STALLERGENES GREER INTERNATIONAL AG